comprehensive prevention strategy (guy de bruyn)

Post on 08-Apr-2018

223 Views

Category:

Documents

0 Downloads

Preview:

Click to see full reader

TRANSCRIPT

  • 8/7/2019 Comprehensive Prevention Strategy (Guy de Bruyn)

    1/18

    Care and Prevention

    in HIV Vaccine Trials:a site perspective

    Guy de Bruyn

    Perinatal HIV Research Unit

    University of the WitwatersrandChris Hani Baragwanath Hospital

    Johannesburg, South Africa

  • 8/7/2019 Comprehensive Prevention Strategy (Guy de Bruyn)

    2/18

    Access to care (modified from Grady)

    Care which is part of the scientific

    design

    Care needed to safely complete the trial Care for injuries and adverse events

    Post trial access

    Ancillary care Care that some participants will

    predictably need

  • 8/7/2019 Comprehensive Prevention Strategy (Guy de Bruyn)

    3/18

    Dialogue?

    a comprehensive care package should

    be agreed upon through ahost/community/sponsor dialogue

    which reaches consensus prior to

    initiation of a trial (UNAIDS 2000,

    #16)

  • 8/7/2019 Comprehensive Prevention Strategy (Guy de Bruyn)

    4/18

    Protocol mandates

    Avoiding pregnancy during the

    vaccination period

    Assessing symptoms of illness Ensuring adequate standard of care to

    control participants

    Counselling pre/post-test, risk reduction,safer sex

    Providing condoms

  • 8/7/2019 Comprehensive Prevention Strategy (Guy de Bruyn)

    5/18

    Care needed to safely complete the trial

    Resuscitation equipment

    Laboratory monitoring of haematologic

    parameters and other clinicallaboratory values of potential interest

    Anaemia

    Leukopaenia

    Alteration of hepatic enzyme tests

  • 8/7/2019 Comprehensive Prevention Strategy (Guy de Bruyn)

    6/18

    Ancillary care in HIV Vaccine trials

    Some questions

    What kind of care is needed?

    For how long? By whom?

    Whose responsibility?

  • 8/7/2019 Comprehensive Prevention Strategy (Guy de Bruyn)

    7/18

    Ancillary care some examples

    Hypertension May be diagnosed incidentally during the conduct

    of trial procedures

    Treatment is lifelong

    Management is multi-modal, i.e. requires attentionto weight, nutrition, exercise, in addition topossible pharmacotherapy

    Facilitating access to services TOP

    Psychosocial support rape/trauma/DV

    Mental illness

    Dental care

  • 8/7/2019 Comprehensive Prevention Strategy (Guy de Bruyn)

    8/18

    What is the standard of prevention?

    HIV counseling and testing

    Some protocols may not provide results in real-

    time, depending on the complexity of ruling out

    vaccine-induced seropositivity Impact on testing outside of the trial setting

    Other VCTs, blood donation, organ donation, testing for

    insurance purposes

    What about partners? Should we offer CHCT and who is able to do that?

  • 8/7/2019 Comprehensive Prevention Strategy (Guy de Bruyn)

    9/18

    More Standard of Prevention

    Risk reduction counselling

    Efforts to standardize that intervention,

    such as pilot efforts within DAIDS

    networks

    Condom promotion vs. provision

    Male / Female / both

    What other means should be used topromote condom uptake

  • 8/7/2019 Comprehensive Prevention Strategy (Guy de Bruyn)

    10/18

    What about additional HIV prevention

    technologies?

    Male circumcision

    STI treatment

    Diagnostics Directed versus syndromic therapy

    Post-exposure prophylaxis

    Pre-exposure prophylaxis Other investigational agents

  • 8/7/2019 Comprehensive Prevention Strategy (Guy de Bruyn)

    11/18

    What is the Threshold of

    Evidence for New PreventionTools?

  • 8/7/2019 Comprehensive Prevention Strategy (Guy de Bruyn)

    12/18

    Cochrane Review of HIV and Circumcision in

    High Risk Heterosexual Men

    Siegfried et al. Lancet Infect Dis 2005

  • 8/7/2019 Comprehensive Prevention Strategy (Guy de Bruyn)

    13/18

    Phambili timelines

    17Mar06. MCC

    submission. GMO

    submission

    8May06. HREC

    submission

    12Sep06. IBC

    submission

    13Oct06. MCC approval

    19Oct06. HREC approval

    24Jan07. First pt

    enrolled

    19 Sep 2007

    STEP trial interim resultsJuly 2005 Orange

    Farm MC trial

    results

    December 2006

    Kenyan and Ugandan

    MC trial results

    7March 2007

    First Phambili

    participant

    provided MC

    8Nov06. IBC approval

    21Nov06. GMO approval

  • 8/7/2019 Comprehensive Prevention Strategy (Guy de Bruyn)

    14/18

    Location ofStudies ofAcceptability

    Thirteen studiesfrom nine sub-Saharan Africancountries

    Bailey R IAS 2007

  • 8/7/2019 Comprehensive Prevention Strategy (Guy de Bruyn)

    15/18

    Public Sector Circumcisions CHB

  • 8/7/2019 Comprehensive Prevention Strategy (Guy de Bruyn)

    16/18

    Local Expertise

  • 8/7/2019 Comprehensive Prevention Strategy (Guy de Bruyn)

    17/18

    Implementing at the Trial Site / Facilities

  • 8/7/2019 Comprehensive Prevention Strategy (Guy de Bruyn)

    18/18

top related